Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 3/20 | 0.57 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.41 |
| ▸ | PIP4K2A | P48426 | 4/20 | 0.38 |
| ▸ | PIP4K2B | P78356 | 4/20 | 0.38 |
| ▸ | PIP4K2C | Q8TBX8 | 1/20 | 0.38 |
| ▸ | JAK2 | O60674 | 1/20 | 0.38 |
| ▸ | JAK1 | P23458 | 1/20 | 0.38 |
| ▸ | TYK2 | P29597 | 1/20 | 0.38 |
| ▸ | JAK3 | P52333 | 1/20 | 0.38 |
| ▸ | IDO1 | P14902 | 1/20 | 0.36 |
| ▸ | TDO2 | P48775 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
| ▸ | IKBKB | O14920 | 1/20 | 0.34 |
| ▸ | CHUK | O15111 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15188916 | 0.87 | CYP3A4 (0.49) | CYP3A4PIP4K2APIP4K2BPIP4K2CJAK2 | |
| SCHEMBL15168607 | 0.86 | CRBN (0.42) | CYP3A4CRBNJAK2JAK1TYK2 | |
| SCHEMBL10083134 | 0.85 | CYP3A4 (0.41) | CYP3A4ABL1 | |
| SCHEMBL1703305 | 0.84 | CYP3A4 (0.57) | CYP3A4CRBNPIP4K2APIP4K2BPIP4K2C | |
| SCHEMBL1703309 | 0.84 | CYP3A4 (0.57) | CYP3A4CRBNPIP4K2APIP4K2BPIP4K2C | |
| SCHEMBL1702764 | 0.81 | CYP3A4 (0.57) | CYP3A4CRBNPIP4K2APIP4K2BPIP4K2C | |
| SCHEMBL15168201 | 0.81 | CRBN (0.38) | CYP3A4CRBNJAK2JAK1TYK2 | |
| SCHEMBL2691431 | 0.80 | CYP3A4 (0.59) | CYP3A4CRBNPIP4K2APIP4K2BPIP4K2C | |
| SCHEMBL16143915 | 0.77 | CYP3A4 (0.54) | CYP3A4CRBNPIP4K2APIP4K2BPIP4K2C | |
| SCHEMBL2450318 | 0.76 | CYP3A4 (0.51) | CYP3A4PIP4K2APIP4K2BPIP4K2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8734777-B2 | Heterocyclic antiviral compounds | ROCHE PALO ALTO LLC (US) | 2014-05-27 | — | — | US | claimed |
| EP-2603501-B1 | HETEROCYCLIC ANTIVIRAL COMPOUNDS | HOFFMANN LA ROCHE (CH) | 2014-05-14 | — | — | EP | claimed |
| US-20130209397-A1 | HETEROCYCLIC ANTIVIRAL COMPOUNDS | ROCHE PALO ALTO LLC (US) | 2013-08-15 | — | — | US | claimed |
| EP-2603501-A1 | HETEROCYCLIC ANTIVIRAL COMPOUNDS | F.HOFFMANN-LA ROCHE AG (CH) | 2013-06-19 | — | — | EP | claimed |
| WO-2012020037-A1 | HETEROCYCLIC ANTIVIRAL COMPOUNDS | F. HOFFMANN-LA ROCHE AG (CH) | 2012-02-16 | — | — | WO | claimed |
| US-8734777-B2 | Heterocyclic antiviral compounds | ROCHE PALO ALTO LLC (US) | 2014-05-27 | — | — | US | disclosed |
| EP-2603501-B1 | HETEROCYCLIC ANTIVIRAL COMPOUNDS | HOFFMANN LA ROCHE (CH) | 2014-05-14 | — | — | EP | disclosed |
| US-20130209397-A1 | HETEROCYCLIC ANTIVIRAL COMPOUNDS | ROCHE PALO ALTO LLC (US) | 2013-08-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130209397-A1 | HETEROCYCLIC ANTIVIRAL COMPOUNDS | EIF2AK2, HCCS, MAVS | CYP3A4 356/4885CRBN 3348/4885PIP4K2A 2155/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.